Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 7, 2010, Pages 739-757

  Chandra, Sunandini ^a   Ruhela, Dipali ^a,b   Deb, Anindita ^a   Vishwakarma, Ram A ^a,c  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b Sirna Therapeutics Inc   (United States)

^c CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Adenosine kinase; Drug discovery; Enolase; Galactofuranosyltransferase; Glycoconjugates; GPI anchor; Leishmania; Mannosyltransferases; Peroxins

Indexed keywords

(4' PHTHALIMIDO)CARBOXAMIDO 3 (4 BROMOBENZYLOXY)BENZENE; 1 OXABICYCLIC BETA LACTAM DERIVATIVE; 2 DEOXY 2 AMINO DEXTRO MANNOSE; 4 [N (3,4 DICHLOROPHENYL)CARBAMOYL]PHTHALIC ANHYDRIDE; 6 METHYLTHIOINOSINE; ALLOPURINOL; AMPHOTERICIN B; ANTILEISHMANIAL AGENT; DEOXYGLUCOSE; EDELFOSINE; FLUORODEOXYGLUCOSE; ILMOFOSINE; MANNOSE ALPHA 1,6 OCTYL ALPHA MANNOSIDE; MANNOSYLTRANSFERASE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PERIFOSINE; PURINE ANTAGONIST; PYRROLE DERIVATIVE; SITAMAQUINE; STIBOGLUCONATE SODIUM; TRANSFERASE INHIBITOR; TUBERCIDIN; UNCLASSIFIED DRUG; VIDARABINE; ANTIPROTOZOAL AGENT; ENOLASE; ENZYME INHIBITOR; GLYCOCONJUGATE; GLYCOSPHINGOLIPID; GLYCOSYLPHOSPHATIDYLINOSITOL; LIPOPHOSPHOGLYCAN; METHYLGLYOXAL; PURINE DERIVATIVE;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG STRUCTURE; DRUG TARGETING; GLYCOBIOLOGY; HUMAN; LEISHMANIA; LEISHMANIASIS; NEPHROTOXICITY; NONHUMAN; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARBOHYDRATE METABOLISM; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG INACTIVATION; ENZYMOLOGY; METABOLISM; MICROBODY; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIPROTOZOAL AGENTS; CARBOHYDRATE METABOLISM; DRUG DISCOVERY; ENZYME INHIBITORS; GLYCOCONJUGATES; GLYCOSPHINGOLIPIDS; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; LEISHMANIA; LEISHMANIASIS; METABOLIC DETOXICATION, DRUG; MICROBODIES; PHOSPHOPYRUVATE HYDRATASE; PURINES; PYRUVALDEHYDE; INACTIVATION, METABOLIC;

EID: 77953562409     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.495125     Document Type: Review

References (150)

1. Leishmaniasis: background information. Geneva, Switzerland: World Health Organization, 2010. Available from: http://www.who.int/leishmaniasis/en/ index.html [Last accessed 22 May 2010]
2. Frezard F, Demicheli C, Rebeiro RR. Pentavalent antimonials: new perspectives for old drugs. Molecules 2009;14:2317-2336
3. Thakur CP, Singh RK, Hassan SM, et al. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans Royal Soc Trop Med Hyg 1999;93:319-323
4. Robinson RF, Nahata MC. A comparitive review of conventional and lipid formulation of Amphotericin B. J Clin Pharm Ther 1999;24:249-257
5. Rakotomanga M, Blanc S, Gaudin K, et al. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007;51:1425-1430
6. Seifert K, Matu S, Perez-Victoria J, et al. Characterization of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 2003;22:380-387
7. Berman J. Miltefosine to treat leishmaniasis. Expert Opin Pharmacother 2005;6:1381-1388
8. Santa-Rita RM, Henriques-Pons A, Barbosa HS, De Castro SL. Effect of lipophospholipid analogues idelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother 2004;54:704-710
9. Azzouz S, Maache M, Garcia RL, Osuna A. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin Pharmacol Toxicol 2005;96:60-65
10. Cabrera-Serra MG, Lorenzo-Morales J, Romero M, et al. In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species. Parasitol Res 2007;100:1155-1157
11. Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 2005;14:1337-1346
12. Mengeling BJ, Beverley SM, Turco SJ. Designing glycoconjugate biosynthesis for an insidious intent: phosphoglycan assembly in Leishmania parasites. Glycobiology 1997;7:873-880
13. Giorgione JR, Turco SJ, Epand RM. Transbilayer inhibition of protein kinase C by the lipophosphoglycan from Leishmania donovani. Proc Natl Acad Sci USA 1996;93:11634-11639
14. Descoteaux A, Matlashewski G, Turco SJ. Inhibition of macrophage protein kinase C-mediated protein phosphorylation by Leishmania donovani lipophosphoglycan. J Immunol 1992;149:3008-3015
15. Proudfoot L, Nikolaev AV, Feng GJ, et al. Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages. Proc Natl Acad Sci USA 1996;93:10984-10989
16. Turco SJ, Descoteaux A. The lipophosphoglycan of Leishmania parasites. Annu Rev Microbiol 1992;46:65-94
17. Spath GF, Epstein L, Leader B, et al. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci USA 2000;97:9258-9263
18. Sacks DL, Modi G, Rowton E, et al. The role of phosphoglycans in Leishmania-sand fly interactions. Proc Natl Acad Sci USA 2000;97:406-411
19. Ilg T. Proteophosphoglycans of Leishmania. Parasitol Today 2000;16:489-496
20. Tachado SD, Gerold P, McConville MJ, et al. Glycosylphosphatidylinositol toxin of Plasmodium induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase-dependent and protein kinase C-dependent signalling pathway. J Immunol 1996;156:1897-1907
21. Nosjean O, Briolay A, Roux B. Mammalian GPI proteins: sorting, membrane residence and functions. Biochim Biophys Acta 1997;1331:153-186
22. Kinoshita T, Inoue N. Dissecting and manipulating the pathway for glycosylphosphatidylinositol anchor biosynthesis. Curr Opin Chem Biol 2000;4:632-638
23. McConville MJ, Menon AK. Recent developments in the cell biology and biochemistry of glycosylphosphatidylinositol lipids. Mol Membr Biol 2000;17:1-16
24. Ferguson MA, Brimacombe JS, Brown JR, et al. The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness. Biochim Biophys Acta 1999;1455:327-340
25. Ferguson MAJ. The structure, biosynthesis and functions of glycosylphosphatidylinositol anchors, and the contributions of trypanosome research. J Cell Sci 1999;112:2799-2809
26. Noda M, Yoon K, Rodan GA, Koppel DE. High lateral mobility of endogenous and transfected alkaline phosphatase: a phosphatidylinositol-anchored membrane protein. J Cell Biol 1987;105:1671-1677
27. McConville MJ, Ferguson MAJ. The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes. Biochem J 1993;294:305-324
28. Maxwell SE, Ramalingam S, Gerber LD, et al. An active carbonyl formed during glycosylphosphatidylinositol addition to a protein is evidence of catalysis by a transamidase. J Biol Chem 1995;270:19576-19582
29. Sharma DK, Vidugiriene J, Bangs JD, Menon AK. A cell-free assay for glycosylphosphatidylinositol anchoring in African trypanosomes. Demonstration of a transamidation reaction mechanism. J Biol Chem 1994;274:16479-16486
30. Santos de Macedo C, Shams-Eldin H, Smith K, et al. Inhibitors of glycosyl-phosphatidylinositol anchor biosynthesis. Biochimie 2003;85:465-472
31. Watanabe R, Murakami Y, Marmor MD, et al. Initial enzyme for glycosylphosphatidylinositol biosynthesis requires PIG-P and is regulated by DPM2. EMBO J 2000;19:4402-4411
32. Milne KG, Ferguson MAJ, Masterson WJ. Inhibition of the GlcNAc transferase of the glycosylphosphatidylinositol anchor biosynthesis in African trypanosomes. Eur J Biochem 1992;208:309-314
33. Urbaniak MD, Crossman A, Chang T, et al. The N-Acetyl- Dglucosaminylphosphatidylinositol De-N-acetylase of glycosylphosphatidylinositol biosynthesis is a zinc metalloenzyme. J Biol Chem 2005;280:22831-22838
34. Crossman AT, Urbaniak MD, Ferguson MAJ. Synthesis of 1-D-6-O-[2-(N- hydroxyaminocarbonyl) amino-2-deoxy-alpha-D-glucopyranosyl]- myo-inositol 1-(n-octadecyl phosphate): a potential metalloenzyme inhibitor of glycosylphosphatidylinositol biosynthesis. Carbohydr Res 2008;343:1478-1481
35. Smith TK, Milne FC, Sharma DK, et al. Early steps in glycosylphosphatidylinositol biosynthesis in Leishmania major. Biochem J 1997;326:393-400
36. Sharma DK, Smith TK, Crossman A, et al. Substrate specificity of the N-acetylglucosaminylphosphatidylinositol de-N-acetylase of glycosylphosphatidylinositol membrane anchor biosynthesis in African trypanosomes and human cells. Biochem J 1997;328:171-177
37. Smith TK, Gerold P, Crossman A, et al. Substrate specificity of the Plasmodium falciparum glycosylphosphatidylinositol biosynthetic pathway and inhibition by species-specific suicide substrates. Biochemistry 2002;41:12395-12406
38. Sharma DK, Smith TK, Welle CT, et al. Differences between the trypanosomal and human GlcNAc-PI de-N-acetylases of glycosylphosphatidylinositol membrane anchor biosynthesis. Glycobiology 1999;9:415-422
39. Smith TK, Sharma DK, Crossman A, et al. Parasite and mammalian GPI biosynthetic pathways can be distinguished using synthetic substrate analogues. EMBO J 1997;16:6667-6675
40. Smith TK, Crossman A, Borissow CN, et al. Specificity of GlcNAc-PI de-N-acetylase of GPI biosynthesis and synthesis of parasite-specific suicide substrate inhibitors. EMBO J 2001;20:3322-3332
41. Maeda Y, Watanabe R, Harris CL, et al. PIG-M transfers the first mannose to glycosylphosphatidylinositol on the lumenal side of the ER. EMBO J 2001;20:250-261
42. Takahashi M, Inoue N, Ohishi K, et al. PIG-B, a membrane protein of the endoplasmic reticulum with a large lumenal domain, is involved in transferring the third mannose of the GPI anchor. EMBO J 1996;15:4254-4261
43. Güther ML, Ferguson MAJ. The role of inositol acylation and inositol deacylation in GPI biosynthesis in Trypanosoma brucei. EMBO J 1995;14:3080-3093
44. Urbaniak MD, Yashunsky DV, Crossman A, et al. Probing enzymes late in the trypanosomal glycosylphosphatidylinositol biosynthetic pathway with synthetic glycosylphosphatidylinositol analogues. ACS Chem Biol 2008;3:625-634
45. Brown JR, Guther MLS, Field RA, Ferguson MAJ. Hydrophobic mannosides act as acceptors for trypanosome alpha-mannosyltransferases. Glycobiology 1997;7:549-558
46. Datema R, Schwarz RT, Jankowski AW. Fluoroglucose-inhibition of protein glycosylation in vivo. Inhibition of mannose and glucose incorporation into lipid-linked oligosaccharides. Eur J Biochem 1980;110:355-361
47. McDowell W, Schwarz RT. Dissecting glycoprotein biosynthesis by the use of specific inhibitors. Biochimie 1988;70:1535-1549
48. Santos de Macedo C, Gerold P, Jung N, et al. Inhibition of glycosyl-phosphatidylinositol biosynthesis in Plasmodium falciparum by C-2 substituted mannose analogues. Eur J Biochem 2001;268:6221-6228
49. Pan YT, De Gespari R, Warren CD, Elbein AD. Formation of unusual mannosamine-containing lipid-linked oligosaccharides in Madin-Darby canine kidney cell cultures. J Biol Chem 1992;267:8991-8999
50. Pan YT, Elbein AD. The effect of mannosamine on the formation of lipid-linked oligosaccharides in canine kidney cells. Arch Biochem Biophys 1985;242:447-456
51. Pan YT, Kamitani T, Bhuvaneswaran C, et al. Inhibition of glycosylphosphatidylinositol anchor formation by mannosamine. J Biol Chem 1992;267:21250-21255
52. Quinlan LR, Kane MT. Nature of glycosylphosphatidylinositols produced by mouse embryonic stem cells. Reproduction 2001;122:785-791
53. Field MC, Medina-Acosta E, Cross GA. Inhibition of glycosylphosphatidylinositol biosynthesis in Leishmania mexicana by mannosamine. J Biol Chem 1993;268:9570-9577
54. Ralton JE, Milne KG, Guther ML, et al. The mechanism of inhibition of glycosylphosphatidylinositol anchor biosynthesis in Trypanosoma brucei by mannosamine. J Biol Chem 1993;268:24183-24189
55. Sevlever D, Rosenberry TL. Mannosamine inhibits the synthesis of putative glycoinositol phospholipid anchor precursors in mammalian cells without incorporating into an accumulated intermediate. J Biol Chem 1993;268:10938-10945
56. Naik RS, Davidson EA, Gowda DC. Developmental stage-specific biosynthesis of glycosylphosphatidylinositol anchors in intraerythrocytic Plasmodium falciparum and its inhibition in a novel manner by mannosamine. J Biol Chem 2000;275:24506-24511
57. Maeda Y, Watanabe R, Harris CL, et al. PIG-M transfers the first mannose to glycosylphosphatidylinositol on the lumenal side of the ER. EMBO J 2001;20:250-261
58. Sutterlin C, Escribano MV, Gerold P, et al. Saccharomyces cerevisiae GPI10, the functional homologue of human PIG-B, is required for glycosylphosphatidylinositol anchor synthesis. Biochem J 1998;332:153-159
59. Ralton JE, McConville MJ. Delineation of three pathways of glycosylphosphatidylinositol biosynthesis in Leishmania mexicana. Eur J Biochem 1992;205:815-825
60. Doering TL, Lu T, Werbovetz KA, et al. Toxicity of myristic acid analogs towards African trypanosomes. Proc Natl Acad Sci USA 1994;91:9735-9739
61. Huang C, Turco SJ. Defective galactofuranose addition in lipophosphoglycan biosynthesis in a mutant of Leishmania donovani. J Biol Chem 1993;268:24060-24066
62. Bakker H, Kleczka B, Gerardy-Schahn R, Routier FH. Identification and partial characterization of two eukaryotic UDP-galactopyranose mutases. Biol Chem 2005;386:657-661
63. Carver MA, Turco SJ. Cell-free biosynthesis of lipophosphoglycan from Leishmania donovani. Characterization of microsomal galactosyltransferase and mannosyltransferase activities. J Biol Chem 1991;266:10974-10981
64. Spath GF, Lye LF, Segawa H, et al. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 2003;301:1241-1243
65. Spath GF, Garraway LA, Turco SJ, Beverley SM. The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci USA 2003;100:9536-9541
66. Rogers ME, Ilg T, Nikolaev AV, et al. Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature 2004;430:463-467
67. Kamhawi S, Ortigao MR, Pham VM, et al. A role for insect galectins in parasite survival. Cell 2004;119:329-331
68. Descoteaux A, Mengeling BJ, Beverley SM, Turco SJ. Leishmania donovani has distinct mannosylphosphoryltransferases for the initiation and elongation phases of lipophosphoglycan repeating unit biosynthesis. Mol Biochem Parasitol 1998;94:27-40
69. Borodkin VS, Ferguson MAJ, Nikolaev AV. Synthesis of beta-D-Galp-(1!4)- alpha-D-Manp methanephosphonate, a substrate analogue for the elongating alpha-D-mannosyl phosphate transferase in the Leishmania. Tetrahedron Lett 2001;42:5305-5308
70. Borodkin VS, Ferguson MAJ, Nikolaev AV. Synthesis of potential bisubstrate inhibitors of Leishmania elongating alpha-D-mannosyl phosphate transferase. Tetrahedron Lett 2004;45:857-862
71. Ruhela D, Chatterjee P, Vishwakarma RA. 1-Oxabicyclic beta-lactams as new inhibitors of elongating MPT-a key enzyme responsible for assembly of cell-surface phosphoglycans of Leishmania parasite. Org Biomol Chem 2005;3:1043-1048
72. Ma D, Russell DG, Beverley SM, Turco SJ. Golgi GDP-mannose uptake requires Leishmania LPG2: a member of eukaryotic family of putative nucleotide sugar transporters. J Biol Chem 1997;272:3799-3805
73. Gaur U, Showalter M, Hickerson MS, et al. Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts. Exp Parasitol 2009;122:182-191
74. Panneerselvam K, Freeze HH. Mannose enters mammalian cells using a specific transporter that is insensitive to glucose. J Biol Chem 1996;271:9417-9421
75. Richard JS, Burchmore RJS, Contreras DR, et al. Genetic characterization of glucose transporter function in Leishmania mexicana. Proc Natl Acad Sci USA 2003;100:3901-3906
76. Contreras DR, Landfear SM. Metabolic changes in glucose transporter-deficient Leishmania mexicana and parasite virulence. J Biol Chem 2006;281:20068-20076
77. Gracy R, Noltmann EA. Studies on phosphomannose isomerase. I. Isolation, homogeinity measurements, and determination of some physical properties. J Biol Chem 1968;243:3161-3168
78. Garami A, Ilg T. The role of phosphomannose isomerase in Leishmania mexicana glycoconjugate synthesis and virulence. J Biol Chem 2001;276:6566-6575
79. Matthijs G, Schollen E, Pirard M, et al. PMM (PMM1), the human homologue of SEC53 or yeast phosphomannomutase, is localized on chromosome 22q13. Genomics 1997;40:41-47
80. Matthijs G, Schollen E, Pardon E, et al. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13 in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat Genet 1997;16:88-92
81. Garami A, Mehlert A, Ilg T. Glycosylation defects and virulence phenotypes of Leishmania mexicana phosphomannomutase and dolicholphosphate- mannose synthase gene deletion mutants. Mol Cell Biol 2001;21:8168-8183
82. Freeze HH, Aebi M. Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity. Biochim Biophys Acta 1999;1455:167-178
83. Kedzierski L, Malby RL, Smith BJ, et al. Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms. J Mol Biol 2006;363:215-227
84. Garami A, Ilg T. Disruption of mannose activation in Leishmania mexicana: GDP-mannose pyrophosphorylase is required for virulence, but not for viability. EMBO J 2001;20:3657-3666
85. Davis AJ, Perugini MA, Smith BJ, et al. Properties of GDP-mannose pyrophosphorylase, a critical enzyme and drug target in Leishmania mexicana. J Biol Chem 2004;279:12462-12468
86. Ilg T, Demar M, Harbecke D. Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice. J Biol Chem 2001;276:4988-4997
87. Keegan FP, Blum JJ. Utilization of a carbohydrate reserve comprised primarily of mannose by Leishmania donovani. Mol Biochem Parasitol 1992;53:193-200
88. Sernee MF, Ralton JE, Dinev Z, et al. Leishmania beta-1,2-mannan is assembled on a mannose-cyclic phosphate primer. Proc Natl Acad Sci USA 2006;103:9458-9463
89. Ralton JE, Naderer T, Piraino HL, et al. Evidence that intracellular beta1-2 mannan is a virulence factor in Leishmania parasites. J Biol Chem 2003;278:40757-40763
90. Roberts WL, Hariprashad J, Rainey PM, Murray HW. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis. Am J Trop Med Hyg 1996;55:444-446
91. Nowicki MW, Tulloch LB, Worralll L, et al. Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis. Bioorg Med Chem 2008;16:5050-5061
92. Faller LD, Baroudy BM, Johnson AM, Ewall RX. Magnesium ion requirements for yeast enolase activity. Biochemistry 1977;16:3864-3869
93. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001;58:902-920
94. Liu KJ, Shih NY. The role of enolase in tissue invasion and metastasis of pathogens and tumor cells. Cancer Mol 2007;3:45-48
95. Avilan L, Calcagno M, Figuera M, et al. Interaction of Leishmania mexicana promastigotes with the plasminogen-plasmin system. Mol Biochem Parasitol 2000;110:183-193
96. Calcagno M, Avilan L, Colasante C, et al. Interaction of different Leishmania mexicana morphotypes with plasminogen. Parasitol Res 2002;88:972-978
97. Maldonado J, Calcagno M, Puig J, et al. A study of cutaneous lesions caused by Leishmania mexicana in plasminogen-deficient mice. Exp & Mol Pathol 2006;80:289-294
98. Bergmann S, Wild D, Diekmann O, et al. Identification of a novel plasmin (ogen)-binding motif in surface displayed alpha-enolase of Streptococcus pneumoniae. Mol Microbiol 2003;49:411-423
99. Vanegas G, Quinones W, Carrasco-Lopez C, et al. Enolase as a plasminogen binding protein in Leishmania mexicana. Parasitol Res 2007;101:1511-1516
100. Albert MA, Haanstra JR, Hannaert V, et al. Experimental and in silico analyses of glycolytic flux control in bloodstream form Trypanosoma brucei. J Biol Chem 2005;280:28306-28315
101. da Silva Giotto MT, Hannaert V, Vertommen D, et al. The crystal structure of Trypanosoma brucei enolase: visualisation of inhibitory metal binding site III and potential as target for selective and irreversible inhibition. J Mol Biol 2003;331:653-665
102. de AS Navarro MV, Dias SMG, Mello LV, et al. Structural flexibility in Trypanosoma brucei enolase revealed by X-ray crystallography and molecular dynamics. FEBS J 2007;274:5077-5089
103. Opperdoes FR. Localization of the initial steps in alkoxyphospholipid biosynthesis in glycosomes (microbodies) of Trypanosoma brucei. FEBS Lett 1984;169:35-39
104. Flaspohler JA, Rickoll WL, Beverly SM, Parsons M. Functional identification of a leishmania gene related to the peroxin 2 gene reveals common ancestry of glycosomes and peroxisomes. Mol Cell Biol 1997;17:1093-1101
105. Opperdoes FR, Borst P. Localization of glycolytic enzymes in a microbody-like organelle in Trypanosoma brucei: the glycosome. FEBS Lett 1977;80:360-364
106. Hart DT, Opperdoes FR. The occurrence of glycosomes (microbodies) in the promastigote stage of four major Leishmania species. Mol Biochem Parasitol 1984;13:159-172
107. Shih S, Hwang HY, Carter D, et al. Localization and targeting of the Leishmania donovani hypoxanthine-guanine phosphoribosyltransferase to the glycosome. J Biol Chem 1998;273:1534-1541
108. Terlecky SR, Fransen M. How peroxisomes arise. Traffic 2000;1:465-473
109. Gould SJ, Keller GA, Subramani S. Identification of peroxisomal targeting signals located at the carboxy terminus of four peroxisomal proteins. J Cell Biol 1988;107:897-905
110. Gould SJ, Keller GA, Schneider M, et al. Peroxisomal protein import is conserved between yeast, plants, insects and mammals. EMBO J 1990;9:85-90
111. Blattner J, Dorsam H, Clayton CE. Function of N-terminal import signals in trypanosome microbodies. FEBS Lett 1995;360:310-314
112. Umasankar PA, Jayakumar PC, Shouche YS, Patole MS. Molecular characterization of hexokinase gene from Leishmania major. J Parasitol 2005;91:1504-1509
113. Moyersoen J, Choe J, Fan E, et al. Biogenesis of peroxisomes and glycosomes: trypanosomatid glycosome assembly is a promising new drug target. FEMS Microbiol Rev 2004;28:603-643
114. Geurra-Giraldez C, Quijada L, Clayton CE. Compartmentation of enzymes in a microbody, the glycosome, is essential in Trypanosoma brucei. J Cell Sci 2002;115:2651-2658
115. Dovey HF, Parsons M, Wang CC. Biogenesis of glycosomes in Trypanosoma brucei: an in vitro model of 3-phosphoglycerate kinase import. Proc Natl Acad Sci USA 1988;85:2598-2602
116. Raychaudhury B, Gupta S, Banerjee S, Das B. Isolation of Leishmania glycosomes by a rapid method. Anal Biochem 2004;332:404-408
117. Trager W. Recent progress in some aspects of the physiology of parasitic protozoa. J Parasitol 1970;56(4):627-633
118. Hammond DJ, Gutteridge WE. Purine and pyrimidine metabolism in the Trypanosomatidae. Mol Biochem Parasitol 1984;13(3):243-261
119. Datta AK, Datta R, Sen B. Antiparasitic chemotherapy: Tinkering with the purine salvage pathway. In: Majumdar HK, editor, Drug targets in Kinetoplastid parasites. Chapter 10. Springer, Berlin; 2008. p. 116-132
120. De Koning HP, Bridges DJ, Burchmore RJ. Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. FEMS Microbiol Rev 2005;29:987-1020
121. Ghosh M, Mukherjee T. Stage-specific development of a novel adenosine transporter in Leishmania donovani amastigotes. Mol Biochem Parasitol 2000;108:93-99
122. Debrabant A, Bastien P, Dwyer DM. A unique surface membrane anchored purine-salvage enzyme is conserved among a group of primitive eukaryotic human pathogens. Mol Cell Biochem 2001;220:109-116
123. Glew RH, Saha AK, Das S, et al. Biochemistry of the Leishmania species. Microbiol Rev 1988;52:412-432
124. Jardim A, Bergeson SE, Shih S, et al. Xanthine phosphoribosyltransferase from Leishmania donovani. Molecular cloning, biochemical characterization, and genetic analysis. J Biol Chem 1999;274:34403-34410
125. Collar CJ, Al-Salabi MI, Stewart ML, et al. Predictive computational models of substrate binding by a nucleoside transporter. J Biol Chem 2009;284:34028-34035
126. Marr JJ, Berens RL, Nelson DJ. Antitrypanosomal effect of allopurinol: conversion in vivo to aminopyrazolopyrimide nucleotides by Trypanosoma cruzi. Science 1978;201:1018-1020
127. Marsden PD, Cuba CC, Barreto AC. Allopurinol treatment in human Leishmania braziliensis braziliensis infections. Trans R Soc Trop Med Hyg 1984;78:701
128. Martinez S, Gonzalez M, Vernaza ME. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis 1997;24:165-169
129. Somoza JR, Skillman AG Jr, Munagala NR, et al. Rational design of novel antimicrobials: Blocking purine salvage in a parasitic protozoan. Biochemistry 1998;37:5344-5348
130. Aronov AM, Munagala NR, Ortiz De Montellano PR, et al. Rational design of selective submicromolar inhibitors of Tritrichomonas foetus hypoxanthine-guanine-xanthine phosphoribosyltransferase. Biochemistry 2000;39:4684-4691
131. Changtam C, de Koning HP, Ibrahim H, et al. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem 2010;45:941-956
132. Datta AK, Bhaumik D, Chatterjee R. Isolation and characterization of adenosine kinase from Leishmania donovani. J Biol Chem 1987;262:5515-5521
133. Vodnala M, Fijolek A, Rofougaran R, et al. Adenosine kinase mediates high affinity adenosine salvage in Trypanosome brucei. J Biol Chem 2008;283:5380-5388
134. Chaudhary K, Darling JA, Fohl LM, et al. Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii. J Biol Chem 2004;279:31221-31227
135. Yadav V, Chu CK, Rais RH, et al. Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. J Med Chem 2004;47:1987-1996
136. Rais RH, Al Safarjalani ON, Yadav V, et al. 6-Benzylthioinosine analogues as subversive substrate of Toxoplasma gondii adenosine kinase: Activities and selective toxicities. Biochem Pharmacol 2005;69:1409-1419
137. Muller S, Liebau E, Walter RD, Krauth-Siegel RL. Thiol-based redox metabolism of protozoan parasites. Trends Parasitol 2003;19:320-328
138. Krauth-Siegel RL, Bauer H, Schirmer RH. Dithiol proteins as guardians of the intracellular redox milieu in parasites: Old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed 2005;44:690-715
139. Thornalley PJ. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990;269:1-11
140. Thornalley PJ. Pharmacology of methyglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996;27:565-573
141. Lo WCT, Westwood ME, McLellan AC, et al. Binding and modification of proteins by methylglyoxal under physiological conditions: a kinetic and mechanistic study with Nalpha-acetylarginine, Nalpha-acetylcysteine, and Nalpha-acetyllysine, and bovine serum albumin. J Biol Chem 1994;269:32299-32305
142. Yadav SK, Singla-Pareek SL, Reddy MK, Sopory SK. Transgenic tobacco plants overexpressing glyoxalase enzymes resist an increase in methylglyoxal and maintain higher reduced glutathione levels under salinity stress. FEBS Lett 2005;579:6265-6271
143. Vickers TJ, Greig N, Fairlamb AH. A trypanothione-dependent glyoxalase I with a prokaryotic ancestry in Leishmania major. Proc Natl Acad Sci USA 2004;101:13186-13191
144. Rath J, Gowri VS, Chauhan SC. A glutathione-specific aldose reductase of Leishmania donovani and its potential implications for methylglyoxal detoxification pathway. Gene 2009;429:1-9
145. Vander Jagt DL, Hunsaker LA. Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem Biol Interact 2003;44:341-351
146. Vickers TJ, Greig N, Fairlamb AH. A trypanothione-dependent glyoxalase I with a prokaryotic ancestry in Leishmania major. Proc Natl Acad Sci USA 2004;101:13186-13191
147. Padmanabhan PK, Mukherjee A, Singh S, et al. Glyoxalase I from Leishmania donovani: a potential target for anti-parasite drug. Biochem Biophy Res Commun 2005;337:1237-1248
148. Sousa Silva M, Barata L, Ferreira AE, et al. Catalysis and structural properties of Leishmania infantum glyoxalase II: Trypanothione specificity and phylogeny. Biochemistry 2008;47:195-204
149. Brenner DS, Jacobs SC, Drachenburg CB, et al. Isolated visceral leishmaniasis presenting as an adrenal cystic mass. Arch Pathol Lab Med 2000;124:1553-1556
150. Sousa Silva M, Ferreira AEN, Tomas AM, et al. Quantitative assessment of the glyoxalase pathway in Leishmania infantum as a therapeutic target by modelling and computer simulation. FEBS J 2005;272:2388-2398